Skip to Content

Fourth Annual Bayesian Biostatistics Conference

Wednesday, January 26 - Friday, January 28, 2011
The University of Texas MD Anderson Cancer Center – Houston, TX

Program Committee

Co-chair: Donald Berry, Ph.D. (MD Anderson Cancer Center)
Co-chair: Telba Irony, Ph.D.
(CDRH, FDA, Silver Spring, MD)
Lurdes Inoue, Ph.D. (University of Washington, Seattle, WA)
Stacy Lindborg, Ph.D.
(Eli Lilly and Company, Indianapolis, IN)
Jeffrey Morris, Ph.D.
(MD Anderson Cancer Center)
Dalene Stangl, Ph.D. (Duke University, Durham, NC)

Program

Wednesday, January 26, 2011

Short Course I: Bayesian Survival Analysis via SAS
Joseph Ibrahim, Ph.D.
Distinguished Professor of Biostatistics
School of Public Health
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Short Course II: Bayes and R (pdf)
James H. Albert, Ph.D.
Professor of Mathematics and Statistics
Bowling Green State University
Bowling Green, Ohio

Keynote Address: Bayesian Opportunities in Comparative Effectiveness Research
Steven N. Goodman, M.D., M.H.S., Ph.D.
Professor of Oncology, Epidemiology and Biostatistics
Editor, Clinical Trials: Journal of the Society for Clinical Trials
Division of Oncology Biostatistics
Johns Hopkins University
Baltimore, Maryland

Invited Session I: Bioinformatics
Organizer: Jeffrey Morris, Ph.D., The University of Texas MD Anderson Cancer Center
Chair: Dalene Stangl, Ph.D., Duke University

Bioinformatics and reproducible research (pdf)
Keith A. Baggerly, Ph.D.
Professor of Bioinformatics and Computational Biology
The University of Texas MD Anderson Cancer Center

Implementing reproducible research
Kevin Coombes, Ph.D.
Professor and Deputy Chair of Bioinformatics
The University of Texas MD Anderson Cancer Center

Reproducible research (pdf)
Frank E. Harrell, Jr., Ph.D.
Professor and Chair, Department of Biostatistics
Vanderbilt University
Nashville, Tennessee

Welcome Reception and Panel Discussion
Organizer & Moderator:
Donald Berry, Ph.D., The University of Texas MD Anderson Cancer Center
Panelists: James H. Albert, Deborah Ashby, Steven N. Goodman, Frank Harrell, Joe Ibrahim, Sharon-Lise Normand, Dalene Stangl, and Janet Wittes

Thursday, January 27, 2011

Invited Session II: Health Policy and Decision Analysis
Organizer and Chair: Dalene Stangl, Ph.D., Duke University

Simulation models to inform health policy: colorectal cancer screening (pdf)
Carolyn M. Rutter, Ph.D.
Senior Investigator
Group Health Research Institute
Seattle, Washington

Percentile-based empirical distribution function estimates for performance evaluation of healthcare providers
Susan M. Paddock, Ph.D.
Senior Statistician and Head of the Statistics Group
RAND Corporation
Santa Monica, California

What role should formal risk-benefit decision making play in the regulation of medicines? (pdf)
Deborah Ashby, Ph.D.
Professor of Medical Statistics and Clinical Trials
Co-director of Imperial Clinical Trials Unit
Imperial College
London, UK

Invited Session III: Bayesian Comparative Effectiveness and Decision Analysis
Organizer: Lurdes Inoue, Ph.D., University of Washington
Chair: Stacy Lindborg, Ph.D., Eli Lilly and Company

Intensive vs extensive margins in comparative effectiveness research (pdf)
Anirban Basu, Ph.D.
Associate Professor of Health Services
Adjunct Associate Professor, Pharmaceutical Outcomes Research and Policy Program
University of Washington
Seattle, Washington

Methods for inferring safety and effectiveness of hip replacements
Sharon-Lise T. Normand, Ph.D.
Professor of Health Care Policy and Biostatistics
Harvard University
Boston, Massachusetts

Use of a Bayesian simulation model to examine the association between technology diffusion and the cost-effectiveness of mammography screening
Ya-Chen Tina Shih, Ph.D.
Associate Professor of Biostatistics
Section of Health Services Research
The University of Texas MD Anderson Cancer Center

Invited Session IV: Using Statistical Methods for Trials of Orphan Products and Rare Diseases
Organizer & Chair: Telba Irony, Ph.D., CDRH, FDA

Analysis of randomized clinical trials of orphan diseases (pdf)
Janet Wittes, Ph.D.
President, Statistics Collaborative, Inc.
Washington, D.C.

Combining prior studies with a current study to make inferences using Bayesian methods
Laura A. Thompson, Ph.D.
Mathematical Statistician
Division of Biostatistics, Center for Devices and Radiological Health
U.S. Food and Drug Administration
Silver Spring, Maryland

Discussant: Donald Berry, Ph.D., The University of Texas MD Anderson Cancer Center - Updating Bayesian Clinical Trials - A Personal Perspective (pdf)

Contributed Session I: Genomics
Chair: Telba Irony, Ph.D., CDRH, FDA

A fully Bayesian hidden Ising model for ChIP-seq data analysis (pdf)
Qianxing Mo, Ph.D.
Research Biostatistician
Department of Epidemiology and Biostatistics
Memorial Sloan-Kettering Cancer Center
New York, New York

Bayesian metrology in metabolomics (pdf)
Andrew Cron
Department of Statistics
Duke University
Durham, North Carolina

Fitting directed acyclic graphs in genomics: an empirical Bayes approach (pdf)
S. H. Heisterkamp, Ph.D.
Senior Principal Statistician, Biostatistics and Research Decision Sciences
Merck Research Laboratories, Oss, The Netherlands
Professor, Groningen Bioinformatics Centre, University of Groningen, Groningen, The Netherlands

Contributed Session II: Oncology
Chair: Donald Berry, Ph.D., The University of Texas MD Anderson Cancer Center

Continual reassessment method for late-onset toxicities using Bayesian data augmentation
Ying Yuan, Ph.D.
Associate Professor of Biostatistics
The University of Texas MD Anderson Cancer Center

Validating risk prediction models using family registries
Wenyi Wang, Ph.D.
Assistant Professor of Bioinformatics and Computational Biology
The University of Texas MD Anderson Cancer Center

Multilevel Bayesian models of zero-inflated longitudinal outcomes and survival times in mesothelioma
Laura Hatfield
Division of Biostatistics
University of Minnesota
Minneapolis, Minnesota

Using information on both short-term response and long-term survival in the design of oncology clinical trials (pdf)
Xuelin Huang, Ph.D.
Associate Professor of Biostatistics
The University of Texas MD Anderson Cancer Center

Poster Session and Discussion 

Friday, January 28, 2011

Contributed Session III: Bayesian Methods
Organizer and Chair: Dalene Stangl, Ph.D., Duke University

Comparative effectiveness? Practical experiences in using Bayesian methods for health technology assessment in order to make population health care decisions
Cathal Walsh, Ph.D.
Lecturer
Department of Statistics, Trinity College Dublin
Dublin, Ireland

Bayesian proportional hazards model for current status data with monotone splines
Bo Cai, Ph.D.
Assistant Professor
Department of Epidemiology and Biostatistics, University of South Carolina
Columbia, South Carolina

Practical issues in the Bayesian design of early clinical studies of treatment efficacy (pdf)
Phil Woodward
Senior Director
Statistics Group, Internal Medicine Research Unit
Pfizer Global R&D

Modeling brain connectivity using multi-modal imaging data (pdf)
Hakmook Kang
Public Health Program, Division of Biology and Medicine
Brown University
Providence, Rhode Island

Invited Session V: Bayesian Applications in Industry: Challenges and Opportunities
Organizer and Chair: Stacy Lindborg, Ph.D., Eli Lilly and Company

The impact of Bayesian methods in drug development: An industry perspective (pdf)
Karen L. Price, Ph.D. 
Lilly Research Laboratories
Eli Lilly and Company
Indianapolis, Indiana

Designing Bayesian software for adaptive clinical trial designs
Scott Berry, Ph.D. 
Berry Consultants, LLC
College Station, Texas

Discussant: Telba Irony, Ph.D., CDRH, FDA

Conference Location

The University of Texas MD Anderson Cancer Center
Robert C. Hickey Auditorium
R11.1400 (Rose Zone, 11th floor)
1515 Holcombe Boulevard
Houston, Texas 77030

Updated February 3, 2011

© 2014 The University of Texas MD Anderson Cancer Center